CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-1.39%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
9.58%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| 1 |
Amazon
AMZN
|
$3.98M |
| 2 |
Procter & Gamble
PG
|
$3.03M |
| 3 |
Booking.com
BKNG
|
$2.86M |
| 4 |
Apple
AAPL
|
$2.77M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
$2.63M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$3.25M |
| 2 |
TSMC
TSM
|
$3.11M |
| 3 |
Carnival Corp
CCL
|
$2.64M |
| 4 |
On Holding
ONON
|
$2.57M |
| 5 |
Advanced Micro Devices
AMD
|
$2.07M |
Sector Composition
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
326
Bicycle Therapeutics
BCYC
$489M
| $13.6K | ﹤0.01% |
679
+340
| +100% | +$6.83K |
|
327
Allogene Therapeutics
ALLO
$251M
| $13.6K | ﹤0.01% |
4,297
+2,385
| +125% | +$7.56K |
|
328
HilleVax
HLVX
$105M
| $13.6K | ﹤0.01% |
1,008
+494
| +96% | +$6.64K |
|
329
HUTCHMED
HCM
$2.71B
| $13.4K | ﹤0.01% |
792
+380
| +92% | +$6.44K |
|
330
Evolus
EOLS
$490M
| $13.3K | ﹤0.01% |
1,459
+713
| +96% | +$6.52K |
|
331
Harrow
HROW
$1.32B
| $13K | ﹤0.01% |
908
+513
| +130% | +$7.37K |
|
332
uniQure
QURE
$970M
| $13K | ﹤0.01% |
1,943
-17,117
| -90% | -$115K |
|
333
Repare Therapeutics
RPTX
$72.2M
| $13K | ﹤0.01% |
1,079
+527
| +95% | +$6.37K |
|
334
Biomea Fusion
BMEA
$111M
| $12.7K | ﹤0.01% |
921
+457
| +98% | +$6.29K |
|
335
Aclaris Therapeutics
ACRS
$230M
| $12.4K | ﹤0.01% |
1,814
+888
| +96% | +$6.08K |
|
336
AnaptysBio
ANAB
$608M
| $12.2K | ﹤0.01% |
682
+335
| +97% | +$6.02K |
|
337
Avidity Biosciences
RNA
$6.41B
| $12.1K | ﹤0.01% |
1,895
+967
| +104% | +$6.17K |
|
338
Theravance Biopharma
TBPH
$712M
| $11.7K | ﹤0.01% |
1,357
+600
| +79% | +$5.18K |
|
339
Castle Biosciences
CSTL
$671M
| $11.6K | ﹤0.01% |
689
+339
| +97% | +$5.73K |
|
340
UroGen Pharma
URGN
$869M
| $10.8K | ﹤0.01% |
774
+467
| +152% | +$6.54K |
|
341
Caribou Biosciences
CRBU
$169M
| $10.8K | ﹤0.01% |
2,258
+1,453
| +180% | +$6.95K |
|
|
MRNS
342
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $10.5K | ﹤0.01% |
1,304
+642
| +97% | +$5.17K |
|
343
Scholar Rock
SRRK
$3.07B
| $10.2K | ﹤0.01% |
1,441
+729
| +102% | +$5.18K |
|
344
Nautilus Biotechnolgy
NAUT
$85.8M
| $10.1K | ﹤0.01% |
3,204
+1,567
| +96% | +$4.95K |
|
|
ITOS
345
DELISTED
iTeos Therapeutics
ITOS
| $10.1K | ﹤0.01% |
924
+455
| +97% | +$4.98K |
|
346
Cullinan Oncology
CGEM
$406M
| $9.91K | ﹤0.01% |
1,095
+579
| +112% | +$5.24K |
|
347
Nurix Therapeutics
NRIX
$714M
| $9.78K | ﹤0.01% |
1,244
+622
| +100% | +$4.89K |
|
348
SIGA Technologies
SIGA
$597M
| $9.56K | ﹤0.01% |
1,821
+887
| +95% | +$4.66K |
|
349
Lyell Immunopharma
LYEL
$231M
| $9.46K | ﹤0.01% |
322
+158
| +96% | +$4.64K |
|
350
Edgewise Therapeutics
EWTX
$1.61B
| $9.36K | ﹤0.01% |
1,634
+805
| +97% | +$4.61K |
|